BioMark Diagnostics is trading at 0.39 as of the 16th of February 2026. This is a 5.41 percent increase since the beginning of the trading day. The stock's lowest day price was 0.39. BioMark Diagnostics has less than a 9 % chance of experiencing financial distress in the next few years and had a fair performance during the last 90 days. The performance scores are derived for the period starting the 18th of November 2025 and ending today, the 16th of February 2026. Click here to learn more.
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.. The company has 83.29 M outstanding shares. More on BioMark Diagnostics
BioMark Diagnostics [BMKDF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioMark Diagnostics's market, we take the total number of its shares issued and multiply it by BioMark Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioMark Diagnostics classifies itself under Healthcare sector and is part of Diagnostics & Research industry. The entity has 83.29 M outstanding shares.
BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations.
Check BioMark Diagnostics Probability Of BankruptcyOwnership AllocationBioMark Diagnostics holds a total of 83.29 Million outstanding shares. BioMark Diagnostics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioMark Ownership Details
Picking the right benchmark for BioMark Diagnostics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in BioMark Diagnostics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for BioMark Diagnostics is critical whether you are bullish or bearish towards BioMark Diagnostics at a given time. Please also check how BioMark Diagnostics' historical prices are related to one of the top price index indicators.
About 55.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.01. BioMark Diagnostics had not issued any dividends in recent years. BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.The quote for BioMark Diagnostics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on BioMark Diagnostics please contact the company at 604 370 0779 or go to https://www.biomarkdiagnostics.com.
BioMark Diagnostics Investment Alerts
BioMark Diagnostics is way too risky over 90 days horizon
BioMark Diagnostics has some characteristics of a very speculative penny stock
BioMark Diagnostics appears to be risky and price may revert if volatility continues
BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 43.93 K. Net Loss for the year was (1.45 M) with profit before overhead, payroll, taxes, and interest of 43.93 K.
BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations.
Roughly 55.0% of the company shares are held by company insiders
BioMark Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioMark Diagnostics's market, we take the total number of its shares issued and multiply it by BioMark Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Technical Drivers
As of the 16th of February 2026, BioMark Diagnostics shows the Risk Adjusted Performance of 0.1274, downside deviation of 7.73, and Mean Deviation of 3.05. BioMark Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for BioMark Diagnostics, which can be compared to its peers. Please confirm BioMark Diagnosticsinformation ratio and the relationship between the maximum drawdown and skewness to decide if BioMark Diagnostics is priced correctly, providing market reflects its regular price of 0.39 per share. As BioMark Diagnostics appears to be a penny stock we also recommend to validate its total risk alpha numbers.
The output start index for this execution was zero with a total number of output elements of sixty-one. BioMark Diagnostics Tanh Of Price Series is a hyperbolic price transformation function.
BioMark Diagnostics Predictive Daily Indicators
BioMark Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioMark Diagnostics otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioMark Diagnostics' time-series forecasting models are one of many BioMark Diagnostics' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioMark Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Our tools can tell you how much better you can do entering a position in BioMark Diagnostics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Stock Screener Now
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Elected by the shareholders, the BioMark Diagnostics' board of directors comprises two types of representatives: BioMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioMark. The board's role is to monitor BioMark Diagnostics' management team and ensure that shareholders' interests are well served. BioMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Other Information on Investing in BioMark OTC Stock
BioMark Diagnostics financial ratios help investors to determine whether BioMark OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.